Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM83 CAR-T for Relapsed or Refractory Osteosarcoma
NCT06412458Phase 1Not yet recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IM83 in osteosarcoma (OS), sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of Treatment Related Adverse Events at 28 days. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
IM83
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT06412458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412458.